AzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
March 31, 2021 16:01 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)
March 10, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
March 08, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors
February 24, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference
February 16, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
February 09, 2021 06:30 ET
|
AzurRx BioPharma, Inc.
Phase 2 Study of oral niclosamide planned for 1H 2021 DELRAY BEACH, Fla., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...
AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference
February 08, 2021 08:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients
January 26, 2021 07:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections
January 12, 2021 08:30 ET
|
AzurRx BioPharma, Inc.
Patent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infectionsCOVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S....
AzurRx BioPharma CEO Issues Letter to Shareholders
January 08, 2021 09:00 ET
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...